Literature DB >> 12458143

In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.

J C Rodríguez1, M Ruiz, M López, G Royo.   

Abstract

The in vitro activity of moxifloxacin, gatifloxacin, levofloxacin and linezolid was evaluated against 234 strains of Mycobacterium tuberculosis isolated in the Southeast of Spain. All drugs tested showed good activity, with an MIC(90) of less than 1 mg/l, and were active against isociacide and rifampicin resistant strains. Three strains were resistant to isoniazid and to the fluoroquinolones, which suggested the existence of mechanisms of resistance not yet described. These new compounds may prove to be therapeutic alternatives for treatment of multi-resistant tuberculosis and further studies should be done to demonstrate their true usefulness. Copyright 2002 Elsevier Science B.V. and International Society of Chemotherapy

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12458143     DOI: 10.1016/s0924-8579(02)00239-x

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  56 in total

1.  Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis.

Authors:  Stephanie Thee; Anthony J Garcia-Prats; Heather R Draper; Helen M McIlleron; Lubbe Wiesner; Sandra Castel; H Simon Schaaf; Anneke C Hesseling
Journal:  Clin Infect Dis       Date:  2014-10-30       Impact factor: 9.079

2.  Clarithromycin significantly increases linezolid serum concentrations.

Authors:  Mathieu S Bolhuis; Richard van Altena; Donald R A Uges; Tjip S van der Werf; Jos G W Kosterink; Jan-Willem C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2010-09-13       Impact factor: 5.191

3.  Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480.

Authors:  J W C Alffenaar; T van der Laan; S Simons; T S van der Werf; P J van de Kasteele; H de Neeling; D van Soolingen
Journal:  Antimicrob Agents Chemother       Date:  2011-01-03       Impact factor: 5.191

4.  In vitro susceptibility of Mycobacterium tuberculosis clinical isolates to garenoxacin and DA-7867.

Authors:  Lucio Vera-Cabrera; Jorge Castro-Garza; Adrian Rendon; Jorge Ocampo-Candiani; Oliverio Welsh; Sung Hak Choi; Kym Blackwood; Carmen Molina-Torres
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

Review 5.  New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.

Authors:  Jossy van den Boogaard; Gibson S Kibiki; Elton R Kisanga; Martin J Boeree; Rob E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

Review 6.  Tuberculosis pharmacotherapy: strategies to optimize patient care.

Authors:  Carole D Mitnick; Bryan McGee; Charles A Peloquin
Journal:  Expert Opin Pharmacother       Date:  2009-02       Impact factor: 3.889

7.  In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years.

Authors:  Tsi-Shu Huang; Yung-Ching Liu; Cheng-Len Sy; Yao-Shen Chen; Hui-Zin Tu; Bao-Chen Chen
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

8.  Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.

Authors:  J W C Alffenaar; P M de Vries; G J Luijckx; D van Soolingen; T S van der Werf; R van Altena
Journal:  Antimicrob Agents Chemother       Date:  2008-03-24       Impact factor: 5.191

Review 9.  Epidemiology and treatment of multidrug resistant tuberculosis.

Authors:  Carole D Mitnick; Sasha C Appleton; Sonya S Shin
Journal:  Semin Respir Crit Care Med       Date:  2008-09-22       Impact factor: 3.119

10.  New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability.

Authors:  Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.